Sanofi, Regeneron launch late-stage cancer studies
Sanofi-Aventis and Regeneron say that they have launched two Phase III trials for aflibercept--or VEGF Trap--with chemotherapy for lung and prostate cancer. The program has enormous potential if it succeeds in Phase III. The injectable therapy is designed to block the formation of abnormal blood vessels. VEGF triggers these new blood vessels to form in a process called angiogenesis. The blockbuster Avastin is currently the leading therapy in this field. Sanofi will provide an update on the program during its R&D day on September 17. The companies believe they can start seeking approval of the drug as early as next year.
- check out the release
Related Articles:
Regeneron, Genentech go head-to-head. Report
Regeneron wins rich pact for VEGF trap. Report
Be the first to comment
More stories about Phase III Genentech injectable Prostate Cancer Sanofi Aventis chemotherapy lung cancer new blood Avastin Vegf Trap Regeneron
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
